These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37497681)

  • 1. Effect of the L74I Polymorphism on Fitness of Cabotegravir-Resistant Variants of Human Immunodeficiency Virus 1 Subtype A6.
    Hu Z; Cordwell T; Nguyen H; Li J; Jeffrey JL; Kuritzkes DR
    J Infect Dis; 2023 Nov; 228(10):1352-1356. PubMed ID: 37497681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of Integrase Sequences from HIV-1 Subtypes A6/A1 on the
    Jeffrey JL; St Clair M; Wang P; Wang C; Li Z; Beloor J; Talarico C; Fridell R; Krystal M; White CT; Griffith S; D'Amico R; Smith K; Van Eygen V; Vingerhoets J; Vandermeulen K; Spreen W; van Lunzen J
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0170221. PubMed ID: 34978890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral Activity of Bictegravir and Cabotegravir against Integrase Inhibitor-Resistant SIVmac239 and HIV-1.
    Hassounah SA; Alikhani A; Oliveira M; Bharaj S; Ibanescu RI; Osman N; Xu HT; Brenner BG; Mesplède T; Wainberg MA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combination of the R263K and T66I Resistance Substitutions in HIV-1 Integrase Is Incompatible with High-Level Viral Replication and the Development of High-Level Drug Resistance.
    Liang J; Mesplède T; Oliveira M; Anstett K; Wainberg MA
    J Virol; 2015 Nov; 89(22):11269-74. PubMed ID: 26311878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.
    Xiao MA; Cleyle J; Yoo S; Forrest M; Krullaars Z; Pham HT; Mesplède T
    Antimicrob Agents Chemother; 2023 May; 67(5):e0138622. PubMed ID: 37071019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genotypic correlates of resistance to the HIV-1 strand transfer integrase inhibitor cabotegravir.
    Rhee SY; Parkin N; Harrigan PR; Holmes S; Shafer RW
    Antiviral Res; 2022 Dec; 208():105427. PubMed ID: 36191692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.
    Hu Z; Kuritzkes DR
    J Virol; 2014 Aug; 88(16):9268-76. PubMed ID: 24899199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.
    Mesplède T; Osman N; Wares M; Quashie PK; Hassounah S; Anstett K; Han Y; Singhroy DN; Wainberg MA
    J Antimicrob Chemother; 2014 Oct; 69(10):2733-40. PubMed ID: 24917583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
    Oliveira M; Ibanescu RI; Anstett K; Mésplède T; Routy JP; Robbins MA; Brenner BG;
    Retrovirology; 2018 Aug; 15(1):56. PubMed ID: 30119633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of combinations of clinically observed HIV integrase mutations on phenotypic resistance to integrase strand transfer inhibitors (INSTIs): a molecular study.
    Cheung PK; Shahid A; Dong W; Lepik KJ; Montaner JSG; Brockman MA; Brumme ZL; Brumme CJ
    J Antimicrob Chemother; 2022 Mar; 77(4):979-988. PubMed ID: 35061879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
    Tzou PL; Rhee SY; Descamps D; Clutter DS; Hare B; Mor O; Grude M; Parkin N; Jordan MR; Bertagnolio S; Schapiro JM; Harrigan PR; Geretti AM; Marcelin AG; Shafer RW;
    J Antimicrob Chemother; 2020 Jan; 75(1):170-182. PubMed ID: 31617907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dolutegravir-Selected HIV-1 Containing the N155H and R263K Resistance Substitutions Does Not Acquire Additional Compensatory Mutations under Drug Pressure That Lead to Higher-Level Resistance and Increased Replicative Capacity.
    Anstett K; Fusco R; Cutillas V; Mesplède T; Wainberg MA
    J Virol; 2015 Oct; 89(20):10482-8. PubMed ID: 26246578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study.
    Vavro C; Ruel T; Wiznia A; Montañez N; Nangle K; Horton J; Buchanan AM; Stewart EL; Palumbo P
    Antimicrob Agents Chemother; 2022 Jan; 66(1):e0164521. PubMed ID: 34694878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment.
    El Bouzidi K; Kemp SA; Datir RP; Murtala-Ibrahim F; Aliyu A; Kwaghe V; Frampton D; Roy S; Breuer J; Sabin CA; Ogbanufe O; Charurat ME; Bonsall D; Golubchik T; Fraser C; Dakum P; Ndembi N; Gupta RK
    J Antimicrob Chemother; 2020 Jun; 75(6):1575-1579. PubMed ID: 32105319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.
    Ndashimye E; Li Y; Reyes PS; Avino M; Olabode AS; Kityo CM; Kyeyune F; Nankya I; Quiñones-Mateu ME; Barr SD; Arts EJ
    J Antimicrob Chemother; 2021 Oct; 76(11):2965-2974. PubMed ID: 34453542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir.
    Pham HT; Alves BM; Yoo S; Xiao MA; Leng J; Quashie PK; Soares EA; Routy JP; Soares MA; Mesplède T
    J Antimicrob Chemother; 2021 Feb; 76(3):639-647. PubMed ID: 33184634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.
    Scutari R; Alteri C; Vicenti I; Di Carlo D; Zuccaro V; Incardona F; Borghi V; Bezenchek A; Andreoni M; Antinori A; Perno CF; Cascio A; De Luca A; Zazzi M; Santoro MM;
    J Glob Antimicrob Resist; 2020 Mar; 20():163-169. PubMed ID: 31330378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors.
    Malet I; Subra F; Charpentier C; Collin G; Descamps D; Calvez V; Marcelin AG; Delelis O
    mBio; 2017 Sep; 8(5):. PubMed ID: 28951475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect on HIV-1 viral replication capacity of DTG-resistance mutations in NRTI/NNRTI resistant viruses.
    Pham HT; Mesplède T; Wainberg MA
    Retrovirology; 2016 Apr; 13(1):31. PubMed ID: 27130466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs.
    Kirichenko A; Lapovok I; Baryshev P; van de Vijver DAMC; van Kampen JJA; Boucher CAB; Paraskevis D; Kireev D
    Viruses; 2020 Jul; 12(8):. PubMed ID: 32752001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.